Clinical Research and Development of Tuberculosis Diagnostics: Moving From Silos to Synergy

Authors

• Payam Nahid, University of California, San Francisco
• Peter S. Kim, National Institute of Allergy and Infectious Diseases, Bethesda
• Carlton A. Evans, Universidad Peruana Cayetano Heredia, Peru
• David Alland, University of Medicine and Dentistry of New Jersey, Newark
• Michael Barer, University of Leicester, United Kingdom
• Jane Diefenbach, PharmaStat LLC, Newark, California
• Jerrold Ellner, Boston University School of Medicine and Medical Center, Massachusetts
• Richard Hafner, National Institute of Allergy and Infectious Diseases, Bethesda
• Carol Dukes Hamilton, 8Family Health International, Durham, North Carolina
• Michael F. Iademarco, Centers for Disease Control and Prevention, Atlanta, Georgia
• Gregory Ireton, Infectious Disease Research Institute, Seattle, Washington
• Michael E. Kimerling, Global Health Program, Bill & Melinda Gates Foundation, Seattle, Washington
• Christian Lienhardt, World Health Organization, Geneva, Switzerland
• William R. MacKenzie, Centers for Disease Control and Prevention, Atlanta, Georgia
• Megan Murray, Harvard School of Public Health, Boston, Massachusetts
• Mark D. Perkins, Foundation for Innovative New Diagnostics, Geneva, Switzerland
• Jamie E. Posey, Centers for Disease Control and Prevention, Atlanta, Georgia
• Teri Roberts, Me´dicins San Frontie`res, Geneva, Switzerland
• Christine Sizemore, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland
• Wendy S. Stevens, University of Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa
• Laura Via, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland
• Sharon D. Williams, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland
• Wing Yew, Chest and Heart Diseases Association, China
• Susan Swindells, University of Nebraska Medical CenterFollow

Date of this Version

2012

Citation

Clinical R&D of Tuberculosis Diagnostics JID 2012:205 (Suppl 2) S159

DOI: 10.1093

Abstract

The development, evaluation, and implementation of new and improved diagnostics have been identified as critical needs by human immunodeficiency virus (HIV) and tuberculosis researchers and clinicians alike. These needs exist in international and domestic settings and in adult and pediatric populations. Experts in tuberculosis and HIV care, researchers, healthcare providers, public health experts, and industry representatives, as well as representatives of pertinent US federal agencies (Centers for Disease Control and Prevention, Food and Drug Administration, National Institutes of Health, United States Agency for International Development) assembled at a workshop proposed by the Diagnostics Working Group of the Federal Tuberculosis Taskforce to review the state of tuberculosis diagnostics development in adult and pediatric populations.